Form 4 for IRD Opus Genetics, Inc.
Accepted 2022-10-20 00:00:00 ET · period of report 2022-10-19 · accession 0001140361-22-037954 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-20 | 2022-10-19 | IRD | Ainsworth Sean | Dir | X - OptEx | $0.00 | +1,574 | 41.2K | +4% | $0 |
| D | 2022-10-20 | 2022-10-19 | IRD | Ainsworth Sean | Dir | X - OptEx | $0.00 | -1,574 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-19 | X | A | 1,574 | $0.00 | 41,239 | D | — | — | |
| 2 | Derivative | Series B Warrant (right to buy) | 2022-10-19 | X | D | 1,574 | $0.00 | 0 | D | $0.00 · 2020-11-19 to 2022-10-20 | 1,574 Common Stock | (F1) The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrants were exercised in full. |